

New commercial activity in the Philippines

REIG JOFRE CONTINUES TO PROGRESS ON ITS PENETRATION IN ASIA WITH THE MARKETING OF AN INJECTABLE ANTIBIOTIC IN THE PHILIPPINES

- Reig Jofre begins the marketing in the Philippines of Bizafox (cefuroxime) 750mg, a cephalosporanic injectable indicated in bacterial infections.
- The Asian market is one of the strategic markets for Reig Jofre, which went from 4% to 7% in the company's sales contribution in 2016.
- Reig Jofre is finalizing the registration of new products for this market.

Barcelona (Spain), September 6, 2017. The pharmaceutical company Reig Jofre has signed a distribution agreement with a local partner to supply the Philippines with cefuroxime 750mg, a cephalosporanic injectable antibiotic indicated in bacterial infections, which is marketed under the name Bizafox 750mg.

The Asian market is one of the strategic markets for Reig Jofre because of its size and growth potential, which in 2016 went from 4% to 7% in the company's sales contribution, driven mainly by the entry into the Japanese market.

The Philippines archipelago, located in Southeast Asia, is made up of more than 7,000 islands and has a population of more than 100 million inhabitants. Currently, Reig Jofre has an important portfolio of products in the process of registration in this market, which is expected to be commercialized in 2018.

Internationalization is one of the strategic growth pillars for Reig Jofre and the specialization in sterile injectable generics for hospital use, developed mostly by Reig Jofre's R & D teams, has been one of the spearheads of internationalization of the company, which generates 60% of its turnover outside Spain, through its own sales network in Europe and commercial relations with more than 130 partners (distributors and licensees) in 64 countries on five continents.



The beginning of commercialization of injectable antibiotics in the Philippines, is added to the creation in 2015 of Reig Jofre Europe, a joint venture in Singapore for the marketing of Reig Jofre products in Southeast Asia and to the agreement formalized with the Japanese Maruishi Pharma for the marketing of state-of-the-art injectables for hospital use in Japan.

Reig Jofre expects to increase the sales of injectable antibiotics in the ASEAN region and reach a million euros in two years thanks to the estimated growth for this cefuroxime 750mg and the marketing of the product portfolio in the registration process.

Reig Jofre closed 2016 with a turnover of 161 million euros.

Get timely updates of Reig Jofre news by registering in the company's **subscription centre** on the corporate website: **www.reigjofre.com**

About Reig Jofre

Founded in Barcelona in 1929, Reig Jofre is a multinational pharmaceutical company with activity structured around two major axes: the main one, own-product manufacture and marketing (RJF Pharma, 80% of total sales) and a complementary one, development and manufacture for third parties (RJF CDMO, 20% of total sales). In its main activity, the company focuses on developing specialised technological products (antibiotics and solutions for injection); specialised therapeutic products for the dermatology, gynaecology and respiratory fields; and dietary supplements and consumer healthcare. The company focuses its R+D activity on developing new indications and/or pharmaceutical forms using known active substances, generic medicines with a particular focus on beta-lactam antibiotics and solutions for injection, topical dermatological products, OTCs and dietary supplements, and in addition develops new innovative molecules in partnership with start-ups and research centres.

Reig Jofre has over 900 employees, 4 development centres and 4 production centres in Europe, direct sales in 7 countries and over 130 business partners in 64 countries across the world. The company closed 2016 with a turnover of 161 million euros.

Reig Jofre is listed on the Spanish Stock Exchange under the ticker RJF. Reig Jofre is listed on the Spanish Stock Exchange under the ticker RJF. Share capital: 63,214,220 shares.

For further information:

Investors and analysts

Gloria Folch

Tel. (+34) 93 480 67 10 – ext. 1241

gloria.folch@reigjofre.com



Media

Inma Santa-Pau

Tel. (+34) 93 480 67 10 – ext. 1242

inma.santapau@reigjofre.com